Corpus Intelligence IC Memo — RADY CHILDRENS HOSPITAL - SAN DIEGO 2026-04-26 05:06 UTC
IC Memo — RADY CHILDRENS HOSPITAL - SAN DIEGO
Investment Committee Memorandum | CA | 401 beds | Grade B | EBITDA uplift $134.2M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

RADY CHILDRENS HOSPITAL - SAN DIEGO

CCN 053303 | SAN DIEGO, CA | 401 beds | April 26, 2026
EBITDA BridgeData Room
B
Investability

1. Target Overview & Investment Thesis

RADY CHILDRENS HOSPITAL - SAN DIEGO is a 401-bed large academic medical center in SAN DIEGO, CA with $1.82B in net patient revenue and a 14.8% operating margin. The hospital serves a payer mix of 0.3% Medicare, 35.6% Medicaid, and 64.0% commercial.

Thesis: Platform Growth. Our ML models identify $134.2M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 14.8% to 22.2% (+736bps).

Net Revenue HCRIS$1.82B
Current EBITDA COMPUTED$269.8M
Operating Margin COMPUTED14.8%
Occupancy HCRIS70.4%
Revenue / Bed COMPUTED$4.5M
Net-to-Gross HCRIS50.4%
Distress Probability ML48.4%

2. Market Context & Competitive Position

414
CA Hospitals
-4.9%
State Median Margin
145
Comparable Hospitals

CA has 414 Medicare-certified hospitals with a median operating margin of -4.9%. The target's margin of 14.8% places it above the state median. Among 145 size-comparable peers (200-802 beds), the median margin is -4.5%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (200-802), prioritizing same-state peers. 145 hospitals in the comp set.

HospitalStateBedsRevenueMargin
RADY CHILDRENS HOSPITAL - SAN (Target)CA401$1.82B14.8%
STANFORD HEALTH CARECA657$6.76B3.7%
UC DAVIS MEDICAL CENTERCA666$3.28B-11.5%
UCSD MEDICAL CENTERCA718$3.06B-7.2%
RONALD REAGAN UCLACA446$2.62B-6.8%
LUCILE PACKARD CHILDRENS HOSPICA394$2.39B-0.8%
LOS ANGELES GENERAL MEDICAL CECA596$1.96B10.2%
UCI MEDICAL CENTERCA397$1.90B-2.5%
CITY OF HOPE NATIONAL MEDICAL CA217$1.83B-10.7%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $134.2M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$38.3M+210bp18mo
Cost to Collect4.5%2.5%$36.5M+200bp12mo
Denial Rate Reduction12.0%6.5%$36.1M+198bp12mo
A/R Days Reduction5200.0%3800.0%$22.2M+122bp9mo
Clean Claim Rate88.0%96.0%$1.2M+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$38.3M
Cost to Collect
$36.5M
Denial Rate Reduction
$36.1M
A/R Days Reduction
$22.2M
Clean Claim Rate
$1.2M
Total EBITDA Uplift$134.2M
Current EBITDA$269.8M
+ RCM Uplift+$134.2M
Pro Forma EBITDA$404.0M
Current Margin14.8%
Pro Forma Margin22.2%
WC Released (1x)$69.9M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$415.1M$3.12B7.52x49.7%
Base (11x exit)10.0x11.0x$415.1M$3.57B8.60x53.8%
Bull Case9.0x11.0x$373.6M$4.15B11.10x61.8%
Bull (12x exit)9.0x12.0x$373.6M$4.63B12.40x65.5%
Bear Case11.0x10.0x$456.6M$2.32B5.07x38.4%
Bear (11x exit)11.0x11.0x$456.6M$2.70B5.90x42.6%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumElevated Medicaid exposure (35.6%)Medicaid reimburses below cost in most states. Mitigant: denial reduction lever has highest impact on Medicaid claims

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 145 hospitals with 200-802 beds
  • Same-state prioritization (n=146)
  • Comp margins: P25=-15.8% / P50=-4.5% / P75=3.7%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.